285 related articles for article (PubMed ID: 20497039)
1. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Miranda E; Maya Pineda H; Öberg D; Cherubini G; Garate Z; Lemoine NR; Halldén G
PLoS One; 2012; 7(10):e46617. PubMed ID: 23056370
[TBL] [Abstract][Full Text] [Related]
3. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
5. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M; Carlisle RC; Hernandez-Alcoceba R; Iggo R; Homicsko K; Fisher KD; Halldén G; Mautner V; Shen Y; Seymour LW
Hum Gene Ther; 2008 Sep; 19(9):873-86. PubMed ID: 18710328
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.
Li LX; Zhang YL; Zhou L; Ke ML; Chen JM; Fu X; Ye CL; Wu JX; Liu RY; Huang W
J Transl Med; 2013 Oct; 11():257. PubMed ID: 24124726
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Halldén G
J BUON; 2009 Sep; 14 Suppl 1():S61-7. PubMed ID: 19785071
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
10. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
12. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
13. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
14. Genetically modified adenoviruses against gliomas: from bench to bedside.
Gomez-Manzano C; Yung WK; Alemany R; Fueyo J
Neurology; 2004 Aug; 63(3):418-26. PubMed ID: 15304571
[TBL] [Abstract][Full Text] [Related]
15. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas.
Jiang H; Gomez-Manzano C; Alemany R; Medrano D; Alonso M; Bekele BN; Lin E; Conrad CC; Yung WK; Fueyo J
Neoplasia; 2005 Jan; 7(1):48-56. PubMed ID: 15720816
[TBL] [Abstract][Full Text] [Related]
16. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
17. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
[TBL] [Abstract][Full Text] [Related]
19. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
20. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
